Azole-resistant central nervous system aspergillosis

Clinical Infectious Diseases

Volumn 48, Issue 8, 2009, Pages 1111-1113

  Van Der Linden, Jan W M ^a,b   Jansen, Rogier R ^a,c   Bresters, Dorine ^d   Visser, Caroline E ^a,c   Geerlings, Suzanne E ^a,c   Kuijper, Ed J ^d   Melchers, Willem J G ^a,b   Verweij, Paul E ^a,b  

^a Department of Medical Microbiology ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; POLYENE ANTIBIOTIC AGENT; VORICONAZOLE;

ADULT; ANAMNESIS; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FUNGUS CULTURE; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; SEROLOGY; STEREOTACTIC BIOPSY;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; CENTRAL NERVOUS SYSTEM INFECTIONS; CHILD; DRUG RESISTANCE, FUNGAL; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROASPERGILLOSIS;

EID: 63649151310     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597465     Document Type: Article

References (12)

1. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
3. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
4. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641-5.
5. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007;356:1481-3.
6. Snelders E, Lee HAL, Kuijpers J, et al. Emergence of azole-resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008;5:e219.
7. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. Wayne, PA:NCCLS, 2002.
8. Mellado E, Garcia-EfFron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro crossresistance to azole antifungals involves a combination of cyp51A alterations. An-timicrob Agents Chemother 2007;51:1897-904.
9. van Leer-Buter C, Takes RP, Hebeda KM, Melchers WT, Verweij PE. Aspergillosis-and a misleading sensitivity result. Lancet 2007; 370:102.
10. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007;50:196-200.
11. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008;46:1200-6.
12. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008;46:2568-72.